Sector News

Sanofi signs autoimmune pact with Lead Pharma

February 18, 2015
Life sciences
Sanofi has linked up with Lead Pharma of the Netherlands to develop drugs for a broad range of autoimmune disorders, including rheumatoid arthritis, psoriasis and inflammatory bowel disease.
 
The pact will focus on therapies directed against the nuclear hormone receptors called ROR gamma (t) which drives the production of key pro-inflammatory proteins including interleukin-17A, IL-17F and the receptor for IL-23. Sanofi and Lead say they have a goal of identifying drug candidates and beginning human trials within three-four years.
 
Financial details were not disclosed but the Dutch biotech will receive an upfront payment and is eligible for the usual development, regulatory and commercial milestones, plus royalties. Christian Antoni, head of Sanofi’s immunology and inflammation R&D, said that “anti-ROR gamma (t) therapies represent a ground-breaking opportunity that we are eager and motivated to pursue”.
 
Meantime still no official announcement from Paris about Sanofi’s new chief executive but numerous news sources, notably Bloomberg, say Olivier Brandicourt, head of Bayer’s healthcare business could be crowned in the newt few days. The Frenchman has been one of the front-runners for the post since Chris Viehbacher was sacked in October.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

How can we help you?

We're easy to reach